CeraPedics To Present at Medtech Insight's ``Investment In Innovation'' Conference.Business Editors/Health/Medical Writers Medtech Insight 2004 In3 San Francisco Conference SAN FRANCISCO--(BUSINESS WIRE)--June 7, 2004 CeraPedics will be presenting on June 8th at Medtech Insight's Prestigious "Investment In Innovation" Event, taking place June 8-9, 2004 at the Palace Hotel in San Francisco, California “San Francisco” redirects here. For other uses, see San Francisco (disambiguation). The City and County of San Francisco (EN IPA: [sænfrənˈsɪskoʊ] . CeraPedics L.L.C. is a privately-held orthopedic company focused on the development of osteobiologic products incorporating P-15(TM). Based on its P-15 technology platform, CeraPedics is currently developing bone graft bone graft Orthopedic surgery Sterilized bony tissue, often of cadaveric origin, used to fill and/or 'sculpt' bone defects Indications Spinal fusion, revision of failed articular prostheses, filling traumatic or malignant bone defects, or periodontal defects. substitutes and a coating for orthopedic implants. P-15 is a synthetic small peptide that mimics the cell-binding domain of Type I collagen, the organic component of autograft autograft: see transplantation, medical. bone. In the body, this cell-binding domain is intimately involved in the binding and migration of cells and initiates the cascade of events leading to new bone formation. CeraPedics' products incorporate P-15 that is identical to the naturally occurring cell-binding domain of Type I collagen. The company possesses the exclusive world-wide orthopedic rights to its P-15 technology through the University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). . CeraPedics' first product, CerOss P-15, is the first and only bone graft substitute using small peptide technology to mimic the organic component of autograft bone. The product is comprised of anorganic bone mineral (ABM ABM: see guided missile. ABM - Asynchronous Balanced Mode ) to which the P-15 is bound. To improve the handling of the material, the combination of ABM/P-15 is suspended in an inert hydrogel hy·dro·gel n. A colloidal gel in which the particles are dispersed in water. hydrogel a gel that contains water. hydrogel Wound care A polymer absorptive wound dressing. See Dressing. . CerOss P-15 is currently under consideration by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. . Peer-reviewed clinical studies in the oral cavity found the active ingredient of CerOss P-15, the ABM/P-15 particles, demonstrated superior efficacy to deminerialized bone matrix (DBM (DeciBels below 1 Milliwatt) A measurement of power loss in decibels using 1 milliwatt as the reference point. A signal received at 1 milliwatt yields 0 dBm. A signal at .1 milliwatt is a loss of 10 dBm. See deciBel and dBA. ) and synthetic bone substitutes. In addition, a large animal spine study and human pilot study for non-union fracture repair suggest the P-15 bone substitute has efficacy equivalent to autograft bone. Based on these studies, CeraPedics believes that CerOss P-15 should be superior to allografts allografts (al´  graf´ts),n.pl the transplantation of tissue between genetically nonidentical individuals of the same species. and synthetics, and equivalent to autograft in orthopedic applications. In addition to the bone substitute development program, CeraPedics is evaluating the coating of metallic orthopedic implants with P-15. In-vitro results demonstrate that P-15 immobilized on a titanium (Ti) surface creates a more hospitable surface for bone to implant integration. Additional in-vivo studies are planned to confirm the in-vitro results. CerOss P-15 will target the rapidly expanding bone graft substitutes market, primarily in spine and trauma procedures. Independent research estimates this market opportunity to be in excess of $900 million. In addition, the P-15 coating could be used on a variety of orthopedic implants including artificial discs, interbody cages, pedicle pedicle /ped·i·cle/ (ped´i-k'l) a footlike, stemlike, or narrow basal part or structure. ped·i·cle n. 1. A constricted portion or stalk. 2. screws and other implants. To learn more about CeraPedics and its P-15 technology, please visit the company's new website www.cerapedics.com. About Medtech Insight Medtech Insight's "Investment In Innovation (In3): A Preview of Early-Stage Medical Technology Companies" conferences are considered the premier forum for senior executives in the medical technology and investment community to preview emerging medtech companies in need of funding, acquisition and/or strategic partnership. In addition to conferences, Medtech Insight publishes the "medtech insight" newsletter, a monthly publication covering the latest trends and innovations in the medical technology industry, analyses of medtech markets through its Reports group, and offers custom consulting and market research. To register for the San Francisco conference or for more information on Medtech Insight, please call Scott Pantel at (949) 219-0150 or (888) 290-2225 toll-free in the U.S., e-mail in3@medtechinsight.com, or visit http://www.medtechinsight.com/in3-11.html. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion